Intravenous Immunoglobulin (IVIG) Attenuates TNF‐Induced Pathologic Bone Resorption and Suppresses Osteoclastogenesis by Inducing A20 Expression. Issue 2 (February 2016) - Lee, Min Joon
Abstract Investigations on the therapeutic effects of intravenous immunoglobulin (IVIG) have focused on the suppression of autoantibody and immune complex‐mediated inflammatory pathogenesis. Inflammatory diseases such as rheumatoid arthritis are often accompanied by excessive bone erosion but the effect of IVIG on osteoclasts, bone‐resorbing cells, has not been studied. Here, we investigate whether IVIG directly regulates osteoclast differentiation and has therapeutic potential for suppressing osteoclast‐mediated pathologic bone resorption. IVIG or cross‐linking of Fcγ receptors with plate‐bound IgG suppressed receptor activator of nuclear factor‐κ B ligand (RANKL)‐induced osteoclastogenesis and expression of osteoclast‐related genes such as integrin β3 and cathepsin K in a dose‐dependent manner. Mechanistically, IVIG or plate‐bound IgG suppressed osteoclastogenesis by downregulating RANKL‐induced expression of NFATC1, the master regulator of osteoclastogenesis. IVIG suppressed NFATC1 expression by attenuating RANKL‐induced NF‐κB signaling, explained in part by induction of the inflammatory signaling inhibitor A20. IVIG administration attenuated in vivo osteoclastogenesis and suppressed bone resorption in the tumor necrosis factor (TNF)‐induced calvarial osteolysis model. Our findings show that, in addition to suppressing inflammation, IVIG directly inhibits osteoclastogenesis through a mechanism involving suppression of RANK signaling. Direct suppression of osteoclast differentiation may provide beneficial effects on preserving bone mass when IVIG is used to treat rheumatic disorders. J. Cell. Physiol. 231: 449–458, 2016. © 2015 Wiley Periodicals, Inc.